Jil et al. also reported that the risk of composite outcome (non-fatal acute myocardial infarction (AMI), non-fatal stroke or all-cause death) was 1.6 times higher in patients receiving intensified treatment with insulin than in patients receiving intensified treatment with DPP-4is following dual-therapy failure20. The gene discussed is INS; the disease is Stroke.